Species-specific anticoagulant and mitogenic activities of murine protein S

Haematologica

Volumn 94, Issue 12, 2009, Pages 1721-1731

  Fernández, José A ^a   Heeb, Mary J ^a   Xu, Xiao ^a   Singh, Itender ^b   Zlokovic, Berislav V ^b   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Mitogenic activities; Murine protein S

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 MACROGLOBULIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BOVINE ACTIVATED PROTEIN C; HUMAN ACTIVATED PROTEIN C; HUMAN PROTEIN S; MURINE ACTIVATED PROTEIN C; MURINE PROTEIN S; PROTEIN S; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOASSAY; MALE; MITOGENESIS; MOUSE; NONHUMAN; PLASMA; SMOOTH MUSCLE FIBER; SPECIES DIFFERENCE;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MITOGENS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTEIN S; RATS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY;

EID: 70349701076     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.009233     Document Type: Article

References (56)

1. Traystman RJ. Animal models of focal and global cerebral ischemia. Ilar J 2003;44:85-95.
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A. Efficacy and safety of recombinant human APC for severe sepsis. N Engl J Med 2001;344:699-709.
3. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong A, Wu Z, et al. APC inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006;12:1278-85.
4. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-72.
5. Jalbert LR, Rosen ED, Moons L, Chan JC, Carmeliet P, Collen D, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998;102:1481-8.
6. Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal ion-dependent inhibition of APC by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of FXa, thrombin, and plasmin. J Biol Chem 1991;266:17606-12.
7. Heeb MJ, España F, Griffin JH. Inhibition and complexation of APC by two major inhibitors in plasma. Blood 1989;73:446-54.
8. Heeb MJ, Schwarz HP, White T, Lammle B, Berrettini M, Griffin JH. Immunoblotting studies of the molecular forms of protein C in plasma. Thromb Res 1988;52:33-43.
9. Fernández JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine APC is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003;30:271-6.
10. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fern G, Griffin JH, et al. APC prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004;41:563-72.
11. Kerschen EJ, Fernández JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant APC. J Exp Med 2007;204:2439-48.
12. Walker FJ. Regulation of bovine APC by protein S: the role of the cofactor protein in species specificity. Thromb Res 1981;22:321-7.
13. Arnljots B, Dahlbäck B. Protein S as an in vivo cofactor to APC in prevention of microarterial thrombosis in rabbits. J Clin Invest 1995;95: 1987-93.
14. Dahlbäck B, Lundwall A, Stenflo J. Primary structure of bovine vitamin K-dependent protein S. Proc Natl Acad Sci USA 1986;83:4199-203.
15. Greengard JS, Fernández JA, Radtke KP, Griffin JH. Identification of candidate residues for interaction of protein S with C4b binding protein and APC. Biochem J 1995;305 (Pt 2):397-403.
16. Katsuura Y, Mochizuki T, Tamura M, Hashide S, Kiyoki M, Nakagaki T, et al. Species specificity of anticoagulant activity of APC: involvement of FV as well as protein S. Thromb Res 1996;82:147-57.
17. Weinstein RE, Walker FJ. Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4b binding protein interaction. J Clin Invest 1990;86:1928-35.
18. Yasuda F, Hayashi T, Tanitame K, Nishioka J, Suzuki K. Molecular cloning and functional characterization of rat plasma protein S. J Biochem (Tokyo) 1995;117:374-83.
19. He X, Dahlbäck B. Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. Eur J Biochem 1993;217:857-65.
20. Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992;79:3203-11.
21. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 2006;11: 2381-99.
22. Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of APC above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem 1997;272:25013-21.
23. Rodriguez de Cordoba S, Perez-Blas M, Ramos-Ruiz R, Sanchez-Corral P, Pardo-Manuel de Villena F, Rey-Compos J. The gene coding for the beta-chain of C4b-binding protein (C4BPB) has become a pseudogene in the mouse. Genomics 1994;21: 501-9.
24. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with FVa and FXa. J Biol Chem 1994;269: 21051-8.
25. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to FVa associated with inhibition of prothrombinase that is independent of APC. J Biol Chem 1993; 268:2872-7.
26. Heeb MJ, Rosing J, Bakker HM, Fernández JA, Tans G, Griffin JH. Protein S binds to and inhibits FXa. Proc Natl Acad Sci USA 1994;91: 2728-32.
27. Koppelman SJ, van't Veer C, Sixma JJ, Bouma BN. Synergistic inhibition of the intrinsic FX activation by protein S and C4b-binding protein. Blood 1995;86:2653-60.
28. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006;103:3106-11.
29. Heeb MJ, Marzec UM, Gruber A, Hanson SR. Protein S is antithrombotic in vivo independent of APC. Blood 2006;108:117A[abstract].
30. Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. Amyloid betaprotein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem 2003;278: 19054-61.
31. Chu MD, Sun J, Bird P. Cloning and sequencing of a cDNA encoding the murine vitamin K-dependent protein S. Biochim Biophys Acta 1994; 1217:325-8.
32. Yan SC, Razzano P, Chao YB, Walls JD, Berg DT, McClure DB, et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (NY) 1990;8:655-61.
33. Lu D, Schmidel DK, Long GL. Structure of mouse protein S as determined by PCR amplification and DNA sequencing of cDNA. Thromb Res 1994;74:135-42.
34. Fernández JA, Heeb MJ, Griffin JH. Identification of residues 413-433 of plasma protein S as essential for binding to C4b-binding protein. J Biol Chem 1993;268:16788-94.
35. Fernández JA, Griffin JH, Chang GT, Stam J, Reitsma PH, Bertina RM, et al. Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. Blood Cells Mol Dis 1998;24:101-12.
36. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation FX, FXa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992;89: 2317-20.
37. Kanthou C, Benzakour O. Cellular effects and signalling pathways activated by the anti-coagulant factor, protein S, in vascular cells protein S cellular effects. Adv Exp Med Biol 2000;476:155-66.
38. Benzakour O, Formstone C, Rahman S, Kanthou C, Dennehy U, Scully MF, et al. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. Biochem J 1995;308:481-5.
39. Smirnov MD, Pyzh MV, Borovikov DV, Atorozhilova AN, Dobrovolsky AB, Golubych VL, et al. Low doses of APC delay arterial thrombosis in rats. Thromb Res 1990;57:645-50.
40. Malm K, Dahlbäck B, Arnljots B. Prevention of thrombosis following deep arterial injury in rats by bovine APC requiring co-administration of bovine protein S. Thromb Haemost 2003;90:227-34.
41. Malm K, Arnljots B, Persson IM, Dahlbäck B. Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human APC in rats. Thromb Res 2007;120: 531-9.
42. Takahara H, Sinohara H. Inhibitory spectrum of mouse contrapsin and alpha-1-antitrypsin against mouse serine proteases. J Biochem (Tokyo) 1983;93:1411-9.
43. Holly RD, Foster DC. Resistance to inhibition by alpha-1-anti-trypsin and species specificity of a chimeric human/bovine protein C. Biochemistry 1994;33:1876-80.
44. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlbäck B, et al. Multifunctional specificity of the protein C/APC Gla domain. J Biol Chem 2006;281:28850-7.
45. Shen L, Dahlbäck B. FV and protein S as synergistic cofactors to APC in degradation of FVIIIa. J Biol Chem 1994;269:18735-8.
46. Takeyama M, Nogami K, Saenko EL, Soeda T, Nishiya K, Ogiwara D, et al. Protein S down-regulates FXase activity independent of APC: specific binding of FVIII(a) to protein S inhibits interactions with FIXa. Br J Haematol 2008;143:409-20.
47. Doering C, Parker ET, Healey JF, Craddock HN, Barrow RT, Lollar P. Expression and characterization of recombinant murine FVIII. Thromb Haemost 2002;88:450-458.
48. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernández JA, et al. Hyper-antithrombotic, non-cytoprotective Glu149Ala-APC mutant. Blood 2009; 113:5970-8.
49. Heeb MJ, Prashun D, Griffin JH, Bouma BN. Plasma protein S contains zinc essential for efficient APC-independent anticoagulant activity and binding to FXa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J 2009, prepublished online Feb. 24. PMID 19244162
50. Maurissen LF, Thomassen MC, Nicolaes GA, Dahllback B, Tans G, Rosing J, et al. Re-evaluation of the role of the protein S-C4b binding protein complex in APC-catalyzed FVa-inactivation. Blood 2008;111: 3034-41.
51. Webb JH, Blom AM, Dahlbäck B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 2002; 169:2580-6.
52. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Schacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4:87-91.
53. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-36.
54. Uehara H, Shacter E. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J Immunol 2008;180:2522-30.
55. Hafizi S, Dahlbäck B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006;273:5231-44.
56. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995;80:661-70.